

Julie L Mcauley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8374827/publications.pdf>

Version: 2024-02-01

38
papers

3,238
citations

257450

24
h-index

302126

39
g-index

41
all docs

41
docs citations

41
times ranked

4515
citing authors

#	ARTICLE	IF	CITATIONS
1	Expression of the 1918 Influenza A Virus PB1-F2 Enhances the Pathogenesis of Viral and Secondary Bacterial Pneumonia. <i>Cell Host and Microbe</i> , 2007, 2, 240-249.	11.0	355
2	MUC1 cell surface mucin is a critical element of the mucosal barrier to infection. <i>Journal of Clinical Investigation</i> , 2007, 117, 2313-2324.	8.2	351
3	Influenza Virus Neuraminidase Structure and Functions. <i>Frontiers in Microbiology</i> , 2019, 10, 39.	3.5	280
4	Activation of the NLRP3 Inflammasome by IAV Virulence Protein PB1-F2 Contributes to Severe Pathophysiology and Disease. <i>PLoS Pathogens</i> , 2013, 9, e1003392.	4.7	195
5	Influenza Enhances Susceptibility to Natural Acquisition of and Disease due to <i>Streptococcus pneumoniae</i> in Ferrets. <i>Journal of Infectious Diseases</i> , 2010, 202, 1287-1295.	4.0	194
6	Kinetics of Coinfection with Influenza A Virus and <i>Streptococcus pneumoniae</i> . <i>PLoS Pathogens</i> , 2013, 9, e1003238.	4.7	184
7	Muc1 Mucin Limits Both <i>Helicobacter pylori</i> Colonization of the Murine Gastric Mucosa and Associated Gastritis. <i>Gastroenterology</i> , 2007, 133, 1210-1218.	1.3	170
8	Influenza Virus Primes Mice for Pneumonia From <i>Staphylococcus aureus</i> . <i>Journal of Infectious Diseases</i> , 2011, 203, 880-888.	4.0	154
9	Reassessing the role of the NLRP3 inflammasome during pathogenic influenza A virus infection via temporal inhibition. <i>Scientific Reports</i> , 2016, 6, 27912.	3.3	150
10	PB1-F2 Proteins from H5N1 and 20th Century Pandemic Influenza Viruses Cause Immunopathology. <i>PLoS Pathogens</i> , 2010, 6, e1001014.	4.7	142
11	The Effects of Influenza A Virus PB1-F2 Protein on Polymerase Activity Are Strain Specific and Do Not Impact Pathogenesis. <i>Journal of Virology</i> , 2010, 84, 558-564.	3.4	98
12	The Role of the Cell Surface Mucin MUC1 as a Barrier to Infection and Regulator of Inflammation. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 117.	3.9	95
13	Reduced mucin sulfonation and impaired intestinal barrier function in the hyposulfataemic NaS1 null mouse. <i>Gut</i> , 2009, 58, 910-919.	12.1	94
14	Bacterial Sinusitis and Otitis Media following Influenza Virus Infection in Ferrets. <i>Infection and Immunity</i> , 2006, 74, 2562-2567.	2.2	86
15	SARS-CoV-2 suppresses IFN γ production mediated by NSP1, 5, 6, 15, ORF6 and ORF7b but does not suppress the effects of added interferon. <i>PLoS Pathogens</i> , 2021, 17, e1009800.	4.7	74
16	Immunopathogenic and Antibacterial Effects of H3N2 Influenza A Virus PB1-F2 Map to Amino Acid Residues 62, 75, 79, and 82. <i>Journal of Virology</i> , 2011, 85, 12324-12333.	3.4	72
17	PB1-F2 Peptide Derived from Avian Influenza A Virus H7N9 Induces Inflammation via Activation of the NLRP3 Inflammasome. <i>Journal of Biological Chemistry</i> , 2017, 292, 826-836.	3.4	70
18	Effect of 1918 PB1-F2 Expression on Influenza A Virus Infection Kinetics. <i>PLoS Computational Biology</i> , 2011, 7, e1001081.	3.2	67

#	ARTICLE	IF	CITATIONS
19	Validation of a single-step, single-tube reverse transcription loop-mediated isothermal amplification assay for rapid detection of SARS-CoV-2 RNA. <i>Journal of Medical Microbiology</i> , 2020, 69, 1169-1178.	1.8	61
20	The role of the NLRP3 inflammasome in regulation of antiviral responses to influenza A virus infection. <i>Antiviral Research</i> , 2017, 148, 32-42.	4.1	44
21	Infrared Based Saliva Screening Test for COVID-19. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 17102-17107.	13.8	42
22	A natural product compound inhibits coronaviral replication in vitro by binding to the conserved Nsp9 SARS-CoV-2 protein. <i>Journal of Biological Chemistry</i> , 2021, 297, 101362.	3.4	35
23	Multi-site assessment of rapid, point-of-care antigen testing for the diagnosis of SARS-CoV-2 infection in a low-prevalence setting: A validation and implementation study. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 9, 100115.	2.9	29
24	Host Immunological Factors Enhancing Mortality of Young Adults during the 1918 Influenza Pandemic. <i>Frontiers in Immunology</i> , 2015, 6, 419.	4.8	27
25	Influenza, but not SARS-CoV-2, infection induces a rapid interferon response that wanes with age and diminished tissue-resident memory CD8 ⁺ T cells. <i>Clinical and Translational Immunology</i> , 2021, 10, e1242.	3.8	25
26	Synergism and Antagonism of Bacterial-Viral Coinfection in the Upper Respiratory Tract. <i>MSphere</i> , 2022, 7, e0098421.	2.9	18
27	Optimal preparation of SARS-CoV-2 viral transport medium for culture. <i>Virology Journal</i> , 2021, 18, 53.	3.4	15
28	Infrared Based Saliva Screening Test for COVID-19. <i>Angewandte Chemie</i> , 2021, 133, 17239-17244.	2.0	15
29	Air-Liquid-Interface Differentiated Human Nose Epithelium: A Robust Primary Tissue Culture Model of SARS-CoV-2 Infection. <i>International Journal of Molecular Sciences</i> , 2022, 23, 835.	4.1	15
30	Recombinant influenza virus expressing HIV-1 p24 capsid protein induces mucosal HIV-specific CD8 T-cell responses. <i>Vaccine</i> , 2016, 34, 1172-1179.	3.8	14
31	Water-Borne Nanocoating for Rapid Inactivation of SARS-CoV-2 and Other Viruses. <i>ACS Nano</i> , 2021, 15, 14915-14927.	14.6	13
32	Evaluation of virucidal activity of residual quaternary ammonium-treated surfaces on SARS-CoV-2. <i>American Journal of Infection Control</i> , 2022, 50, 325-329.	2.3	11
33	Rapid evolution of the PB1-F2 virulence protein expressed by human seasonal H3N2 influenza viruses reduces inflammatory responses to infection. <i>Virology Journal</i> , 2017, 14, 162.	3.4	9
34	Induction of memory cytotoxic T cells to influenza A virus and subsequent viral clearance is not modulated by PB1-F2-dependent inflammasome activation. <i>Immunology and Cell Biology</i> , 2016, 94, 439-446.	2.3	7
35	Multi-site point of care assessment of Abbott ID NOW rapid molecular test for SARS-CoV-2 in a low-prevalence setting. <i>Pathology</i> , 2021, 53, 912-914.	0.6	6
36	Passaging of an influenza A(H1N1)pdm09 virus in a difluoro sialic acid inhibitor selects for a novel, but unfit I106M neuraminidase mutant. <i>Antiviral Research</i> , 2019, 169, 104542.	4.1	5

#	ARTICLE	IF	CITATIONS
37	The Efficacy of Common Household Cleaning Agents for SARS-CoV-2 Infection Control. <i>Viruses</i> , 2022, 14, 715.	3.3	5
38	Liquid Chalk Is an Antiseptic against SARS-CoV-2 and Influenza A Respiratory Viruses. <i>MSphere</i> , 2021, 6, e0031321.	2.9	1